Tetrahydroaminoacridine and Alzheimer's disease

Tetrahydroaminoacridine (THA, tacrine), a cholinesterase inhibitor with several other actions that could enhance cognitive function,1 has passed the Food and Drug Administration's stringent licensing procedure for use in treating “mild to moderate” Alzheimer's disease.2 Since the first claim of its efficacy in Alzheimer's disease in a controlled trial in 19863 further studies have been almost equally divided between those reporting benefit for some patients with Alzheimer's disease and those reporting no benefit4 (such as the study by Maltby in this issue p 8795). No washout period or inadequate outcome measures are apparent in most studies, and comparison between them is also complicated by the concurrent use of lecithin in some studies. The dosage of tetrahydroaminoacridine varies widely, between 20 mg and 114 mg a day, as does the duration of treatment, from …

[1]  D. Riesenberg,et al.  Tacrine for Alzheimer's disease. , 1994, JAMA.

[2]  Anthony F Jorm,et al.  Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial , 1994, BMJ.

[3]  J. Rennie,et al.  Vitamin K prophylaxis in the newborn--again. , 1994, Archives of disease in childhood.

[4]  M. Klebanoff,et al.  The risk of childhood cancer after neonatal exposure to vitamin K , 1993, The New England journal of medicine.

[5]  G. Wilcock,et al.  An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. , 1993, Age and ageing.

[6]  E. Pfeiffer.  Clinical diversity in late onset Alzheimer's disease , 1993 .

[7]  Martin R. Farlow,et al.  A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.

[8]  J. O'Brien,et al.  The effects of tacrine on regional cerebral blood flow in Alzheimer's disease , 1992 .

[9]  R F Woolson,et al.  A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. , 1992, The New England journal of medicine.

[10]  T Dierks,et al.  Functional imaging procedures in dementias: mapping of EEG and evoked potentials , 1992, Acta neurologica Scandinavica. Supplementum.

[11]  E. Byrne.  Diffuse Lewy body disease: Disease, spectrum disorder or variety of Alzheimer disease , 1992 .

[12]  S. Eagger,et al.  Serum levels of tacrine in relation to clinical response in Alzheimer's disease , 1992 .

[13]  W. Lambert,et al.  Pharmacokinetics and Safety of a New Solution of Vitamin K1(20) in Children with Cholestasis , 1992, Journal of pediatric gastroenterology and nutrition.

[14]  Robert H. Perry,et al.  Senile dementia of Lewy body type A clinically and neuropathologically distinct form of Lewy body dementia in the elderly , 1990, Journal of the Neurological Sciences.

[15]  T. Arie,et al.  Tetrahydroaminoacridine (THA) in Alzheimer's disease. , 1989, BMJ.

[16]  A. Kling,et al.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. , 1986, The New England journal of medicine.

[17]  Anthony F Jorm.  Subtypes of Alzheimer's Dementia: a conceptual analysis and critical review , 1985, Psychological Medicine.

[18]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[19]  A. Kling,et al.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer??s type , 1987 .